Description
The Story of GLP-1: A Historical Journey in the Treatment of Diabetes and Obesity offers a compelling narrative about the discovery and development of the hormone GLP-1, which has revolutionized modern approaches to diabetes and obesity. Award-winning scientist Professor Jens Juul Holst, alongside co-authors Professor Sten Madsbad, Professor Jens Meldgaard Bruun, and Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen, trace the scientific breakthroughs and clinical advances that have made GLP-1 therapies, such as Ozempic and Wegovy, essential tools for improving blood sugar control and promoting meaningful, lasting weight loss in patients worldwide.The book explores the rising global prevalence of obesity and diabetes, emphasizing the urgent need for innovative solutions. It critically examines traditional treatments, noting their limitations in sustaining weight loss or reducing complications. The narrative details the paradigm shift brought by GLP-1 medications, including liraglutide and semaglutide, which offer improved cardiovascular outcomes and significant health benefits. The authors also address ongoing challenges of accessibility and affordability, prompting important societal discussions about equitable distribution and funding for these lifechanging therapies.- Presents a unique perspective on the historical and physiological context of these advancements and the discovery and development of GLP-1- Provides readers with evidence-based insights, reinforcing the credibility of the information and supporting informed decision-making in practice- Discusses diabetes, particularly type 2 diabetes and metabolic syndrome to establish a clear framework for understanding the relevance of GLP-1 therapies
Table of Contents
1. The Incretin Effect2. GLP-1 and the Gastrointestinal Tract3. GLP-1 and Food Intake4. GLP-1 and Diabetes5. GLP-1 and Diabetes Treatment6. GLP-1 receptor Agonists (GLP-1 RA)7. Weight Loss and Diabetes Treatment8. GLP-1 and Weight Loss9. GLP-1 and society10. The Discovery and Development of Human GLP-1
